Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
about
Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connectionPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer TherapeuticsTargeting the apoptosis pathway in hematologic malignanciesThe Open Form Inducer Approach for Structure-Based Drug Design.Undecylprodigiosin induced apoptosis in P388 cancer cells is associated with its binding to ribosomeA phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyA multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family membersThe Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsInhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent processObatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.Mitochondrial permeability transition pore as a selective target for anti-cancer therapyAn evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesGX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells.Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.How to unleash mitochondrial apoptotic blockades to kill cancers?Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.Therapeutic approaches in myelofibrosis.Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.Manipulating the apoptotic pathway: potential therapeutics for cancer patients.Small molecules as pro-apoptotic anticancer agents.Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Targeting cancer cell mitochondria as a therapeutic approach: recent updates.Cancer and necroptosis: friend or foe?Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells.Management of myelofibrosis: JAK inhibition and beyond.Structure and Substrate Sequestration in the Pyoluteorin Type II Peptidyl Carrier Protein PltLBH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells.Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors.Novel Therapies for Myelofibrosis.
P2860
Q24607513-2FC933CE-CB69-41D8-B2A8-EFC425014EF1Q26771601-8863650F-4FC1-4776-990A-4039DAA73FDBQ27010154-41F30912-5C94-439B-823B-ACA57A805CA5Q27024422-4DB12385-147A-43CA-BB37-FC8EE147F557Q28554455-3C239EE8-4432-42BC-B49D-E11EB7D504AEQ31120131-E161C7F1-E1BD-443A-A402-02C22C22D915Q33414307-EA8C162D-A893-4DA4-9E46-AE18ABCC7569Q34004454-22F0F4BB-4EEE-458C-9C1F-4B509329C3FBQ34294097-A526D4D0-9E21-445F-AE93-3F37EEB3F65EQ34608671-250D815C-2FDD-48CA-B6BE-7B6EFE4AC41EQ35180339-FD0D2327-1690-4DC3-8AD7-068BB022B9E3Q35975387-681BCF19-544A-4E2A-A21B-5AC0DCB55DA7Q36057887-AAAEBE8E-4F0E-42A9-8BFE-B9111B26EA2DQ36337960-6D4AE514-F219-474B-82A7-ACED706D1E1FQ36668047-CB563953-9EB2-437A-97A6-5FE4831018F2Q36696524-8944A03B-4442-4A36-B541-B06065AED546Q36759341-9CA89C86-5126-42DE-B36D-8073C0656C92Q37521403-9779ABF2-DDEB-42DB-ABA2-45672800893BQ37587294-F89E6442-7170-4DBC-9E2B-67805065B411Q37589245-50220257-87C4-448B-BF0C-55B10712ECFBQ37860336-8212007A-A507-4A06-AE6C-236B392C5F9CQ37983083-B30CB718-56C4-4011-8477-4333D64C229FQ38061861-3CBB82F7-ABAD-4048-AD85-F4B915C0FCEDQ38100790-E8327772-3D20-437F-846A-7B3B73C393A9Q38115574-C09DD134-7FAB-4C9B-97E7-C931850B3D50Q38162939-2B176E1F-36DB-4E7E-BA9E-74D2C20ADA2EQ38193997-73E346E3-36C6-4B96-80EB-5FE4CA1D5062Q38567540-A3E9704A-9A8C-4289-B673-48156FCAD7A1Q38668524-DCE0DD50-B5CE-45F9-A2E1-F76919250557Q38799139-D93D379D-28BD-4E52-8195-71B02BF3F1A9Q38999607-D3151B48-1D41-45F4-8022-B27497E0FCBBQ39232415-30754E1E-D1BA-44C3-B74A-C99179FC3D03Q40718758-23B0CA4C-A70D-4C19-868E-933B52DF431FQ41694352-BD9D96EC-6833-4D04-9D5F-EBA0009354C5Q41740316-B7DC738C-059A-495C-839A-DA87C7BCE72FQ42061450-770513B1-CA97-4BBC-8F02-003421A09471Q52817185-D4BAEFD3-8591-4D9B-8A98-A2C47219D2C8
P2860
Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase II study of obatoclax me ...... r patients with myelofibrosis.
@ast
Phase II study of obatoclax me ...... r patients with myelofibrosis.
@en
type
label
Phase II study of obatoclax me ...... r patients with myelofibrosis.
@ast
Phase II study of obatoclax me ...... r patients with myelofibrosis.
@en
prefLabel
Phase II study of obatoclax me ...... r patients with myelofibrosis.
@ast
Phase II study of obatoclax me ...... r patients with myelofibrosis.
@en
P2093
P50
P356
P1476
Phase II study of obatoclax me ...... r patients with myelofibrosis.
@en
P2093
Ekatherine Asatiani
Elliott Winton
Khaled El-Shami
Sameer A Parikh
William Walsh
P304
P356
10.3816/CLML.2010.N.059
P407
P577
2010-08-01T00:00:00Z